PlainRecalls
FDA Drug Moderate Class II Terminated

Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).

Reported: February 12, 2014 Initiated: December 18, 2013 #D-1075-2014

Product Description

Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).

Reason for Recall

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
112,800 tablets
Distribution
Nationwide
Location
Horsham, PA

Frequently Asked Questions

What product was recalled?
Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).. Recalled by Teva Pharmaceuticals USA. Units affected: 112,800 tablets.
Why was this product recalled?
Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 12, 2014. Severity: Moderate. Recall number: D-1075-2014.